title: Clinical observation of three dimensional conformal radiotherapy with tamoxifen in treatment of postoperative malignant glioma.
abstract: OBJECTIVE
  To evaluate the efficacy and adverse effects of three dimensional conformal radiotherapy (3D-CRT) with tamoxifen in treating patients with postoperative malignant glioma.
  
  
  METHODS
  60 patients of postoperative malignant glioma were randomly assigned into two groups, 30 patients were treated with 3D-CRT plus tamoxifen (treatment group), and the other 30 patients with 3D-CRT plus temozolomide (control group). All patients were radiated by 6MV X-ray, 2.0 Gy per fraction, once daily, with a total dose (DT) of 56~60 Gy. Tamoxifen was delivered at 60 mg /m2/d, temozolomide was given at 75 mg/m2/d. All patients were treated with concurrent radiotherapy.
  
  
  RESULTS
  One, 2, 3 year survival rates of treatment and control group were 63.3%, 30.0%, 23.0% and 70.0%, 33.3%, 26.7%, respectively (χ2=0.01, 0.23, 0.09, P>0.05). The rate of thromboembolism in treatment group was 6.7%.
  
  
  CONCLUSIONS
  Therapeutic efficacy of two groups was similar, but it was more cost- effective in treatment group, and toxicity did not increase.
authors.affiliation: Department of Radiation Oncology, Affiliated People's Hospital of Yangzhou University, Taixing, China E-mail : huangxinen06 @163.com.
authors.forename: Shao-Bing
authors.initials: SB
authors.lastname: Zhou
authors.forename: Yang-Chen
authors.initials: YC
authors.lastname: Liu
authors.forename: Xiao-Xiang
authors.initials: XX
authors.lastname: Yin
authors.forename: Wen-Xiu
authors.initials: WX
authors.lastname: Ding
authors.forename: Xin-Wei
authors.initials: XW
authors.lastname: Guo
authors.forename: Liang
authors.initials: L
authors.lastname: Gu
authors.forename: Xin-En
authors.initials: XE
authors.lastname: Huang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D003131:Combined Modality Therapy / Q000009:adverse effects / Q000191:economics / Q000379:methods*; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D005910:Glioma / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011184:Postoperative Period; D020266:Radiotherapy, Conformal / Q000379:methods*; D011897:Random Allocation; D015996:Survival Rate; D013629:Tamoxifen / Q000191:economics / Q000627:therapeutic use*; D000077204:Temozolomide; D013923:Thromboembolism / Q000453:epidemiology; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D018906:Antineoplastic Agents, Alkylating; D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen; D003606:Dacarbazine; D000077204:Temozolomide